“Latest Stem Cells News”

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience’s 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL. Rafael Gonzalez, Ph.D., Director of Research and Development for DaVinci Biosciences LLC will present the work during the conference on October 20, 2009 and be available to answer questions regarding the study, following his presentation.

“We are excited to share the findings of this study in such a public forum. This study successfully demonstrates not only the safety and feasibility of using autologous adult stem cells for treating spinal cord injuries, but also that the clinical procedure for delivering these cells is safe as well,” said Dr. Gonzalez.

The abstract highlights data from 8 patients that underwent the treatment which used stem cells harvested from the patients’ own bone marrow to side step any immune rejection response, and features the documented evaluations from a 2 year post surgical follow up period. Furthermore, it illustrates new data obtained from 46 patients that participated in the study using stem cells harvested from the patients’ own bone marrow. Magnetic resonance imaging data of the spinal cord, obtained from those who were treated, shows morphological changes within the damaged areas. In addition, this study documents the improved function of bladder control, ASIA motor scoring and Barthel scoring.

“Although this study was successful, we will build upon the results that we have achieved and the methods we have developed to progress into a larger clinical program. Responsibly, but timely developing ways to improve the quality of life for those affected with injuries or diseases, such as spinal cord injury, is the core of our mission and we are optimistic about the opportunity of conducting future studies in the US,” said Dr. Gonzalez.

from http://www.dvbiosciences.com/

Incoming search terms:

SANUWAVE Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

Dr. Myron Spector, PhD, Professor of Orthopaedic Surgery (Biomaterials) at Harvard Medical School, Director of Orthopaedic Research at Brigham and Women’s Hospital and Director of Tissue Engineering at VA Boston Healthcare System, was an invited guest speaker at the Conference. The Bone–Tec Congress featured an international scientific forum to discuss progresses in modern bone tissue regeneration and extended a worldwide network to exchange findings on the latest developments.

Dr. Spector’s team employed SANUWAVE’s Pulsed Acoustic Cellular Expression (PACE™) technology in preclinical research to create autogenous sources of stem cells for bone tissue engineering. Results support the proposition that PACE™ could be employed as a non-invasive technique to cause proliferation and thickening of the cambium layer of the femur’s periosteum for the subsequent intraoperative harvesting of progenitor stem cells days later for bone or cartilage regeneration.

PACE™ stimulated a dramatic proliferation and thickening (up to 10 fold) of osteoprogenitor stem cells, precursors to bone and cartilage cells, in the cambium layer of the periosteum in the femur of the adult rats within 4 days. Neovascularization and new bone formation within the thickened periosteum were also evident after 4 days.

Dr. Spector said, “This research has shown great potential. Through more study, this technology could further advance tissue engineering autologous transplant techniques towards clinical applications such as bone reconstruction and cartilage defect repair.” (…)

from http://www.sanuwave.com

Incoming search terms:

Russia’s Stem Cell Institute said on Wednesday it plans to raise up to 165 million roubles ($5.53 million) in what will be the country’s first initial public offering since the financial crisis erupted last year.

If the IPO goes ahead as expected, Stem Cell Institute would have an implied market capitalisation of 825 million roubles.

Stem Cell Institute set an indicative price range of the IPO at between 9 and 11 roubles per ordinary share and the offering will comprise approximately 15 million ordinary shares.

from http://www.reuters.com/article/rbssHealthcareNews/idUSL562611120091007

Incoming search terms:

What are the differences between embryonic, adult and induced pluripotent stem cells? Where do the experts expect the next medical application will be for stem cells? Do stem cells promote regeneration? How are cell types interacting? How can induced pluripotent stem (iPS) cells revolutionize drug discovery? Can cell therapies be made into a viable business? How close are we to finding the right business model? Are investors interested in stem cells today? What is the political and ethical landscape like now that the Obama administration has taken over the White House?

This is the Episode 1 of the Stem Cell Review, aired on October 1st, 2009

from http://www.biobusiness.tv/videos/201

Incoming search terms:

On Sept. 14, 46-year-old Hatem Faraj suffered a major heart attack while watching Monday Night Football on TV.
Tuesday, the Wesley Chapel man joined the cutting edge of heart disease research, becoming the area’s first participant in a study to see if a patient’s own stem cells can regenerate his damaged heart muscle.

The procedure he had at Pepin Heart at University Community Hospital in Tampa is part of a University of Florida research program. Its aim is improving chances of long-term survival and reducing heart transplants. Using stem cells to regenerate heart tissue has been studied for several years in animals and humans, producing mixed results. Still, the therapy is considered promising for millions of Americans with heart failure (…)

The most appealing part of the study is that a patient’s own stem cells are used, he said. “It won’t hurt you to participate,” Matar said. “I would encourage physicians to refer their patients.”

Researchers are looking at many questions surrounding the therapy: how many stem cells to infuse into the heart, how long it will take to see results, how soon after a cardiac event should treatment be delivered, how much tissue regeneration can patients expect. The long-term effects of such therapy are unknown.

The University of Florida is one of five U.S. medical centers involved in three federally funded stem cell regeneration clinical trials. Bay area hospitals with cardiac care programs were asked help enroll the almost 300 patients needed for the 2 1/2-year-long study.

“It will be a challenge,” says Dr. Charles Lambert, medical director at Pepin, the first satellite center in Florida to recruit a study participant. Lambert says that’s because patients who have just survived a heart attack must undergo two medical procedures: one to harvest bone marrow in order to get the stem cells, and another to infuse cells in the heart.

Two-thirds of participants will be infused with stem cells; the others will receive a cell-free solution. Patients — including Faraj — won’t know if they actually receive stem cells, standard protocol in medical research (…)

Because it was the first procedure at a satellite center, a UF medical team traveled to Tampa to assist with the bone marrow harvest earlier Tuesday and drive the cells back to Gainesville. There, scientists isolated the heart and vascular stem cells, extracted and purified them and handed them off to a second medical team. They drove the little bag of cells, about six tablespoons worth, back to Tampa.

Faraj was only mildly sedated during the hourlong infusion, in which the stem cells (or a cell-free solution) were sent to his heart through a catheter inserted in the groin and threaded through the femoral artery to his heart. He was smiling and talking with hospital staff immediately afterward (…)

from http://www.tampabay.com/news/health/study-hopes-to-use-patients-own-stem-cells-to-mend-broken-hearts/1041081

Incoming search terms:

Hikers know that moss on a tree trunk always points north. According to new research by Israeli and German scientists, this ancient plant may also provide a new “compass” for stem cell research, telling scientists how better to program stem cells for medical purposes.

Dr. Nir Ohad of Tel Aviv University‘s Department of Plant Sciences and Prof. Ralf Reski of the University of Freiburg have discovered a new use for the Polycomb group proteins (PcG) found in moss. They reported their findings recently in the journal Development. PcG proteins play an important role in telling stem cells how to develop, they believe. The research is being funded by the German-Israeli Foundation.

Moss is a kind of plant that shares basic development processes with those found in humans. “We may not have found the switch that turns stem cells into tissue,” comments Dr. Ohad, “but we have found a key component which makes this switch work.”

In their new paper, the researchers describe an ancient mechanism that alters the way DNA organizes inside the cell nucleus, which in turn, affects gene expression. This finding has important implications in stem cell therapies, which can go awry if implanted stem cells aren’t reprogrammed properly (…)

from http://www.sciencedaily.com/releases/2009/09/090929133242.htm

Incoming search terms: